

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company or its subsidiaries.*



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

## **INSIDE INFORMATION POTENTIAL ISSUANCE OF SHARES BY CR PHARMACEUTICAL COMMERCIAL**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

### **COMMENCEMENT OF PRE-BIDDING PROCESS FOR THE POTENTIAL ISSUANCE BY CR PHARMACEUTICAL COMMERCIAL**

The board of directors (the “**Board**”) of China Resources Pharmaceutical Group Limited (the “**Company**”) hereby announces that China Resources Pharmaceutical Commercial Group Company Limited (華潤醫藥商業集團有限公司) (“**CR Pharmaceutical Commercial**”), a wholly-owned subsidiary of the Company, has proposed to issue new shares by way of public bidding via a legally established equity exchange in accordance with the relevant regulations of the Measures for the Supervision and Administration of the Trading of State-Owned Assets of Enterprises (企業國有資產交易監督管理辦法) (the “**Potential Issuance**”). The number of new shares to be issued and the amount of proceeds to be raised under the Potential Issuance will be determined in due course having considered various factors including the market conditions.

On 30 October 2023, the pre-bidding process in relation to the Potential Issuance (the “**Pre-Bidding Process**”) commenced via the China Beijing Equity Exchange. CR Pharmaceutical Commercial has published an application form for pre-disclosure of information for capital raising on 30 October 2023 in relation to the Pre-Bidding Process (the “**Application**”) on the website of the China Beijing Equity Exchange. Full text of the Application is available on the website of the China Beijing Equity Exchange at [www.cbex.com.cn](http://www.cbex.com.cn). Following the completion of the Pre-Bidding Process, the Potential Issuance remains subject to the formal public bidding process on the China Beijing Equity Exchange.

The Board wishes to emphasize that no binding agreement with respect to the Potential Issuance has been entered into by CR Pharmaceutical Commercial as at the date of this announcement, and there is no assurance that any definitive transaction with respect to the Potential Issuance will materialize. The Company will make further announcement(s) in compliance with the Listing Rules and/or Part XIVA of the SFO as and when appropriate or required.

**As CR Pharmaceutical Commercial may or may not enter into a binding agreement with respect to the Potential Issuance, and even if it decides to do so, the Potential Issuance may be subject to fulfilment of closing conditions and may or may not proceed to completion for various reasons. Accordingly, shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.**

*For ease of reference, the names of the PRC established companies or entities have been included in this announcement in both the Chinese and English languages, and in the event of any inconsistency, the Chinese version shall prevail.*

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**Han Yuewei**  
*Chairman*

Beijing, 30 October 2023

*As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong and Mr. Tao Ran as executive Directors, Mr. Lin Guolong, Mdm. Guo Wei, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.*